Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863449 | 0.84 | CYP11B1 (0.39) | CYP11B1CYP11B2GRM2HTR2AKCNH2 | |
| SCHEMBL115263 | 0.78 | CYP11B1 (0.43) | CYP11B1CYP11B2GRM2HTR2AKCNH2 | |
| SCHEMBL114628 | 0.78 | CYP11B1 (0.43) | CYP11B1CYP11B2GRM2HTR2AKCNH2 | |
| SCHEMBL3635565 | 0.78 | TAAR1 (0.52) | CYP11B1CYP11B2HTR2ACYP2A6TP53 | |
| SCHEMBL10483862 | 0.78 | CYP11B1 (0.43) | CYP11B1CYP11B2GRM2HTR2AKCNH2 | |
| SCHEMBL10282267 | 0.78 | SMN1; SMN2 (0.49) | CYP11B1CYP11B2NPC1TP53PKM | |
| SCHEMBL3804734 | 0.77 | CYP11B1 (0.42) | CYP11B1CYP11B2GRM2CYP2E1CYP2A6 | |
| SCHEMBL23124232 | 0.75 | CYP2A6 (0.48) | CYP11B1CYP11B2GRM2HTR2ACYP2A6 | |
| SCHEMBL9156125 | 0.75 | SMN1; SMN2 (0.46) | CYP11B1CYP11B2GRM2HTR2AKCNH2 | |
| SCHEMBL8662195 | 0.75 | CYP11B1 (0.41) | CYP11B1CYP11B2GRM2HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101379065-A | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same | CRYSTALGENOMICS INC (KR) | 2009-03-04 | — | — | CN | claimed |
| EP-2890676-B1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9670195-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-06-06 | — | — | US | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-9522883-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2016-12-20 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218147-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-08-06 | — | — | US | disclosed |
| EP-2890679-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890676-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890675-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890678-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032187-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032185-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032184-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032188-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | CYP11B1 2425/4885CYP11B2 2713/4885GRM2 3725/4885 |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | GAA, ENGASE, OGA | CYP11B1 1200/4885CYP11B2 949/4885GRM2 1307/4885 |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | CYP11B1 2425/4885CYP11B2 2713/4885GRM2 3725/4885 |
| US-20150218147-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | CYP11B1 2425/4885CYP11B2 2713/4885GRM2 3725/4885 |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | CYP11B1 2425/4885CYP11B2 2713/4885GRM2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.